- Clinical trial will recruit approximately 1400 patients in 10
countries starting in July
- Participants will be randomised to receive the low molecular
weight Heparin enoxaparin or current standard of care for up to 3
weeks from the time of diagnosis
- The study is supported through an investigator initiated grant
from Sanofi
LONDON, June 30, 2020 /PRNewswire/ -- TRI will conduct an
open-label randomized controlled trial of community-based early
thromboprophylaxis named ETHIC (Early Thromboprophylaxis in
COVID-19). Eligible patients will have newly-diagnosed
Covid-19 and also have been identified with an increased risk of
complications of infection due to age and comorbidities.
The study was designed in response to recent evidence suggesting
that severe COVID-19 infections are associated with increased
frequency of thrombosis.
Symptomatic patients with COVID-19 receiving the LMWH (via
enoxaparin) will be compared with patients receiving the standard
of care. The follow up period for assessing outcomes including
hospitalization and mortality is at 21 days, with further
assessments at 50 days and 90 days.
Symptomatic COVID-19 patients receiving the LMWH (via
enoxaparin) will be compared with patients receiving the standard
of care. . The follow up period for assessing outcomes including
hospitalization and mortality is at 21 days, with further
assessments at 50 days and 90 days.
The study will be funded by an investigator-initiated study
grant provided by Sanofi.
TRI Director Ajay Kakkar said:
"Our understanding of the role of thrombosis and anticoagulation
in COVID-19 is rapidly evolving. We greatly appreciate the
opportunity to engage our global network of researchers in the
evaluation of anticoagulation in COVID-19 in the community setting
for the first time. We are immensely grateful to the colleagues and
patients who will participate in this important study."
The Thrombosis Research Institute is a leader in innovative
solutions for the detection and treatment of thrombosis. Sanofi is
a global biopharmaceutical company focused on improving human
health.
Logo -
https://mma.prnewswire.com/media/1195593/ETHIC_Logo.jpg